The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED
NCT02120079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37
Last updated 2024-06-26
Summary
This research study is looking to see if in vivo confocal microscopy (IVCM) imaging can be used to confirm clinical findings (which are noted by the doctor during an eye exam) and measure the immune response to the inflammation in the subject's cornea (the front part of the eyeball).
Additionally, this study is trying to determine the effectiveness of two eye-drops, Lotemax and artificial tears, in treating the inflammation associated with DED by measuring changes in immune cells with IVCM imaging. The subject will be treated with either Lotemax (loteprednol) or artificial tears (a lubricating eye drop with no medication). Lotemax is an FDA-approved steroid eye-drop that is often used to treat inflammation associated with DED. Artificial tears are approved by the FDA for treatment of dryness associated with DED.
Thus, this study is designed to determine the effects of the administration of a topical steroid, Lotemax, over a treatment period of 6 weeks, using novel methods of detecting efficacy. In order to achieve the aforementioned goal, subjects will be prospectively randomized to one of two treatment arms - Lotemax or artificial tear. Both groups will follow the same study schedule.
Conditions
Interventions
- DRUG
-
Lotemax
Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
- DRUG
-
Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
- DIAGNOSTIC_TEST
-
In Vivo Confocal Microscopy (IVCM)
In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
Sponsors & Collaborators
-
Tufts Medical Center
lead OTHER
Principal Investigators
-
Pedram Hamrah, MD · Tufts Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 89 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-02-28
- Primary Completion
- 2017-04-30
- Completion
- 2018-01-28
Countries
- United States
Study Locations
More Related Trials
-
Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease
NCT04413279 ·Status: COMPLETED ·Phase: PHASE4
-
Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD
NCT02621593 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
NCT01207752 ·Status: COMPLETED ·Phase: NA
-
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
NCT01521507 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema
NCT04225611 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Open Label Comparing the Short Term Efficacy of Lacrisert
NCT03079271 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease
NCT05865457 ·Status: RECRUITING ·Phase: NA
-
Topical Steroid Treatment For Dry Eye
NCT02218827 ·Status: UNKNOWN ·Phase: NA
-
A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®
NCT02028312 ·Status: WITHDRAWN ·Phase: PHASE4
-
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
NCT00407043 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis
NCT05028907 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
NCT04555694 ·Status: COMPLETED ·Phase: PHASE4
-
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
NCT04527887 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
NCT03055832 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Low-Level Light Therapy on Meibomian Glands Study
NCT05859295 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
NCT03396913 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
NCT01456780 ·Status: COMPLETED ·Phase: PHASE4
-
Does the Use of a Moisture Chamber Decrease the Incidence of Corneal Abrasions in Critically Ill Pediatric Patients?
NCT00129077 ·Status: COMPLETED ·Phase: NA
-
Intense Pulsed Light in Meibomian Gland Dysfunctions
NCT04147962 ·Status: COMPLETED
-
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
NCT01276223 ·Status: COMPLETED ·Phase: PHASE2
-
IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD
NCT03265652 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
NCT02322528 ·Status: COMPLETED ·Phase: NA
-
Correlation of Different Signs for Assessment of Dry Eye Syndrome
NCT01753687 ·Status: COMPLETED ·Phase: NA
-
Moderate-to-Severe Dry Eye Disease Relief Using Acoltremon
NCT07268599 ·Status: ENROLLING_BY_INVITATION
-
PMCF Study to Evaluate Performance and Safety of "Distilled Waters-based Eyedrops" Used to Relieve Dry Eye Symptoms
NCT05825586 ·Status: COMPLETED ·Phase: NA